Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Eiger Biopharma (EIGR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 213,979
  • Shares Outstanding, K 19,260
  • Annual Sales, $ 0 K
  • Annual Income, $ -52,390 K
  • 60-Month Beta 1.35
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.81
  • Number of Estimates 4
  • High Estimate -0.72
  • Low Estimate -0.90
  • Prior Year -0.82
  • Growth Rate Est. (year over year) +1.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.43 +6.52%
on 05/09/19
11.90 -6.64%
on 04/18/19
-1.92 (-14.74%)
since 04/17/19
3-Month
10.43 +6.52%
on 05/09/19
15.33 -27.53%
on 04/03/19
-2.17 (-16.34%)
since 02/15/19
52-Week
8.40 +32.26%
on 11/20/18
18.00 -38.28%
on 05/18/18
-5.69 (-33.87%)
since 05/17/18

Most Recent Stories

More News
Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Apelian will step...

EIGR : 11.11 (+0.91%)
Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for the...

EIGR : 11.11 (+0.91%)
Eiger to Present at ChinaBio® Partnering Forum 2019

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President...

EIGR : 11.11 (+0.91%)
Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $11.00 per share. All of...

EIGR : 11.11 (+0.91%)
Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Amit K. Sachdev,...

EIGR : 11.11 (+0.91%)
Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress(TM) 2019

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced end of study post-treatment...

EIGR : 11.11 (+0.91%)
Research Report Identifies Aerojet Rocketdyne, Knight-Swift Transportation, Potbelly, Aqua Metals, OrthoPediatrics, and Eiger BioPharmaceuticals with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Aerojet Rocketdyne Holdings, Inc....

PBPB : 5.77 (+3.41%)
KNX : 30.93 (-2.24%)
AJRD : 36.42 (-1.25%)
AQMS : 1.96 (-3.92%)
KIDS : 40.10 (-2.48%)
EIGR : 11.11 (+0.91%)
Eiger BioPharmaceuticals to Participate in Conferences in April

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will present...

EIGR : 11.11 (+0.91%)
Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced Phase 2 PREVENT study results...

EIGR : 11.11 (+0.91%)
Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President...

EIGR : 11.11 (+0.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade EIGR with:

Business Summary

Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California.

See More

Key Turning Points

2nd Resistance Point 11.48
1st Resistance Point 11.30
Last Price 11.11
1st Support Level 10.87
2nd Support Level 10.62

See More

52-Week High 18.00
Fibonacci 61.8% 14.33
Fibonacci 50% 13.20
Fibonacci 38.2% 12.07
Last Price 11.11
52-Week Low 8.40

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar